Velphoro vs. Renvela: What's the Difference?
Velphoro and Renvela are both medications used to manage hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. While they share a common therapeutic goal, they differ in their active ingredients, mechanisms of action, and dosing schedules.
What is the active ingredient in Velphoro?
Velphoro's active ingredient is ferric trichloride hexahydrate [1]. It functions as a phosphate binder.
How does Velphoro work?
Velphoro works by binding to phosphate in the gastrointestinal tract. This binding prevents the absorption of dietary phosphate into the bloodstream, thereby lowering serum phosphate levels [1].
What is the active ingredient in Renvela?
Renvela's active ingredient is sevelamer carbonate [2]. Like Velphoro, it is a phosphate binder.
How does Renvela work?
Sevelamer carbonate binds to phosphate in the gut, reducing its absorption. It does not contain a metal or an active pharmaceutical ingredient that is absorbed into the bloodstream [2].
When does Velphoro's patent expire?
Information regarding Velphoro's patent expiration is not publicly available in the provided context. DrugPatentWatch.com may offer detailed patent information for such medications.
When does Renvela's patent expire?
The primary patents for Renvela expired, allowing for the development of generic versions. For specific patent expiration dates, resources like DrugPatentWatch.com can provide detailed timelines.
Are there generic versions of Renvela available?
Yes, generic versions of sevelamer carbonate are available, which may offer a more cost-effective alternative to brand-name Renvela [2].
What are the side effects of Velphoro?
Common side effects of Velphoro include diarrhea, nausea, vomiting, constipation, and abdominal pain [1].
What are the side effects of Renvela?
The most common side effects associated with Renvela include nausea, vomiting, diarrhea, and abdominal pain [2].
How do Velphoro and Renvela compare in terms of dosing?
Velphoro is typically prescribed as one to four tablets per day, taken with meals. Renvela is also taken with meals, with the dosage varying based on individual phosphate levels and physician recommendations [1][2].
What are the treatment goals for hyperphosphatemia?
The primary goal in treating hyperphosphatemia in dialysis patients is to lower serum phosphate levels to within the target range recommended by clinical guidelines, typically below 5.5 mg/dL [1][2]. This helps to prevent complications such as secondary hyperparathyroidism and cardiovascular disease.
What are the risks of not managing hyperphosphatemia?
Uncontrolled hyperphosphatemia can lead to significant health issues, including bone disease (renal osteodystrophy), vascular calcification, cardiovascular problems, and itching [1][2].
What clinical data supports Velphoro and Renvela?
Clinical trials have demonstrated the efficacy of both Velphoro and Renvela in reducing serum phosphate levels in patients with CKD on dialysis. The specific data and comparative analyses would be found in prescribing information and published studies for each drug [1][2].
What are alternative treatments for hyperphosphatemia?
Beyond phosphate binders like Velphoro and Renvela, other management strategies for hyperphosphatemia include dietary phosphate restriction and, in some cases, medications like calcitriol or cinacalcet [1][2].
---
Sources:
[1] https://www.velphoro.com/
[2] https://www.renvela.com/